RS-2024-00462636

Nonclinical Development of Enhanced Safety Macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging

PharmGen Science, Inc.

OTHERS | **Preclinical**

Product Type	MRI contrast agent
Indication	MRI liver imaging
Target	Gadolinium Based Liver-specific Contrast Agent
MoA(Mechanism of Action)	• Gadolinium contrast agents enhance contrast between normal and pathological tissues by shortening T1 and T2 relaxation times through their paramagnetic properties in a magnetic field • Hepatocyte uptake via SLC transporters is higher in normal cells than in HCCs due to lower transporter expression in HCCs, resulting in contrast differences between normal and tumor tissues
Competitiveness	• First Macrocyclic gadolinium-based contrast agent for hepatobiliary • RD1303 is a liver-specific magnetic resonance imaging contrast agent that has up to 50% hepatobiliary excretion • The improved kinetic stability reduces the risk of gadolinium-induced adverse effects and enhanced safety compared to linear contrast agents
Development Stage	Preclinical
Route of Administration	Intravenous injection

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund